⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NGNE News
Neurogene, Inc. Common Stock
Form 8-K
sec.gov
NGNE
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
businesswire.com
NGNE
Form 8-K
sec.gov
NGNE
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
NGNE
Form 8-K
sec.gov
NGNE
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
businesswire.com
NGNE
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
NGNE
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
businesswire.com
NGNE
Form 8-K
sec.gov
NGNE
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
businesswire.com
NGNE